Quanterix Corp
NASDAQ:QTRX

Watchlist Manager
Quanterix Corp Logo
Quanterix Corp
NASDAQ:QTRX
Watchlist
Price: 11.75 USD 0.26% Market Closed
Market Cap: 451m USD
Have any thoughts about
Quanterix Corp?
Write Note

Quanterix Corp
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Quanterix Corp
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Quanterix Corp
NASDAQ:QTRX
Total Liabilities & Equity
$411.3m
CAGR 3-Years
-8%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Total Liabilities & Equity
$100.4B
CAGR 3-Years
11%
CAGR 5-Years
12%
CAGR 10-Years
9%
Danaher Corp
NYSE:DHR
Total Liabilities & Equity
$80.6B
CAGR 3-Years
-1%
CAGR 5-Years
6%
CAGR 10-Years
9%
Mettler-Toledo International Inc
NYSE:MTD
Total Liabilities & Equity
$3.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
5%
Agilent Technologies Inc
NYSE:A
Total Liabilities & Equity
$11B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
1%
IQVIA Holdings Inc
NYSE:IQV
Total Liabilities & Equity
$27.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
24%
No Stocks Found

Quanterix Corp
Glance View

Market Cap
451.2m USD
Industry
Life Sciences Tools & Services

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 460 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers at extremely low concentrations in blood, serum and other fluids. Its products include HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, and 2470 Arrayer. The company also supplies NF-Light antibodies and ELISA kits, which offer solutions for the detection of neurofilament light (Nf-L) for the development of therapeutics and diagnostics for neurodegenerative conditions. Its portfolio of available kits spans multiple therapeutic areas, including cardiology, infectious disease, inflammation, neurology, and oncology. The company provides services through its Simoa Accelerator Laboratory.

QTRX Intrinsic Value
16.88 USD
Undervaluation 30%
Intrinsic Value
Price

See Also

What is Quanterix Corp's Total Liabilities & Equity?
Total Liabilities & Equity
411.3m USD

Based on the financial report for Jun 30, 2024, Quanterix Corp's Total Liabilities & Equity amounts to 411.3m USD.

What is Quanterix Corp's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
30%

Over the last year, the Total Liabilities & Equity growth was -4%. The average annual Total Liabilities & Equity growth rates for Quanterix Corp have been -8% over the past three years , 30% over the past five years .

Back to Top